E. Joosens - Concepedia

Author

E. Joosens

Also Known As

Brigitte Honhon, E J Joosens, E Joosens, E. J. Joosens, E. Joosens, E.J.R. Joosens, Els Joosens, Eric J. Joosens, Eric Joosens, Joosens, Eric

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

ZNA Middelheim Hospital Universitair Ziekenhuis Leuven Universitair Ziekenhuis Brussel GZA Ziekenhuizen Campus Sint-Augustinus KU Leuven

About

E. Joosens is an author at ZNA Middelheim Hospital specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	688
2	Health Sciences	4	4	348
3	Anesthesia	1	1	11
4	Cell Biology	1	1	13
5	Emergency Medicine	1	1	11

E. Joosens

Publications

775

Citations

H-Index

Page 1

	Year	Citations
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma Bart Neyns, Jan Sadones, E. Joosens, Annals of Oncology MedicineMetronomic TherapyRecurrent High-grade GliomaNeurologyHigh-grade Gliomas	2009	239
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 C.-H. Köhne, Jacques De Grève, J. T. Hartmann, Annals of Oncology Gastrointestinal OncologyMedicineInfusional 5-Fluorouracil/folinic AcidPharmacologyColorectal Cancer	2007	161
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study D. Schrijvers, C. van Herpen, Joseph Kerger, Annals of Oncology Neck CancerMedicineUnresectable HeadHead And Neck CancerCancer Treatment	2004	86
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85
A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma Bart Neyns, C. Chaskis, E. Joosens, Cancer Investigation Cancer ManagementPathologySurgeryHigh-grade GliomasGlioma	2008	39
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study Eric Van Cutsem, Luc Dirix, J-L. van Laethem, British Journal of Cancer	2005	37
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. F Mazzeo, Lionel Duck, E. Joosens, PubMed	2011	34
Phase I–II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) D. Schrijvers, C. van Herpen, J. Kerger, European Journal of Cancer Malignant DiseaseMedicinePathologyHead And Neck CancerCancer Treatment	1999	16
Comparison of modified technetium-99m albumin and technetium-99m red blood cells for equilibrium ventriculography. Anne‐Sophie Hambye, Kristin Verbeke, R Vandermeiren, PubMed	1997	16
Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium Els Everaert, Bart Neyns, E. Joosens, Journal of Neuro-Oncology Neuro-oncologyGliomaMedicineCompassionate Use ProgramMetronomic Therapy	2004	15

Page 1